• High-Dose Maternal Tamoxifen Causes Fetal Malformations in M

  2026-04-28

  This study demonstrates that high-dose maternal exposure to tamoxifen, a selective estrogen receptor modulator, induces dose-dependent limb and craniofacial malformations in mouse embryos. These findings highlight critical considerations for the use of tamoxifen in developmental and CreER-mediated gene knockout research models.

• KR-12 (human) TFA: Antimicrobial Mechanisms & Biofilm Eviden

  2026-04-28

  KR-12 (human) TFA is the minimal human antimicrobial peptide with robust activity against multidrug-resistant pathogens and biofilms. This article details its molecular mechanism, spectrum, and evidence benchmarks, clarifying its anti-inflammatory and immunomodulatory research value.

• Gepotidacin’s Efficacy in Urogenital Gonorrhea: Phase 2 Insi

  2026-04-27

  This phase 2 trial evaluated gepotidacin, a novel bacterial topoisomerase inhibitor, for single-dose treatment of uncomplicated urogenital gonorrhea. The study’s findings suggest high efficacy and a promising safety profile, underscoring gepotidacin’s potential as an alternative in the face of rising antibiotic resistance.

• Phosbind Acrylamide: Precision Phosphate-Binding Reagent in

  2026-04-27

  Phos binding reagent (Phosbind) acrylamide enables quantitative, antibody-free detection of protein phosphorylation states through SDS-PAGE mobility shifts. This workflow-centric guide spotlights its application for signaling pathway studies and highlights troubleshooting strategies and protocol enhancements that deliver reproducible, publication-grade results.

• Methicillin Sodium Salt: Applied Workflows in MSSA Research

  2026-04-26

  Methicillin sodium salt enables high-fidelity modeling of methicillin-sensitive Staphylococcus aureus (MSSA) infections, supporting robust susceptibility testing and resistance mechanism studies. This article details optimized protocols, troubleshooting insights, and the product’s unique value for bench scientists targeting gram-positive pathogens.

• Amitriptyline HCl: Elevating CNS Drug Discovery with Mechani

  2026-04-25

  This thought-leadership article explores the mechanistic and translational power of Amitriptyline HCl for CNS research. We dissect its multi-receptor inhibition profile, bridge the latest in vitro blood-brain barrier (BBB) modeling advances, and provide actionable guidance for experimental design—positioning APExBIO’s high-purity compound as a strategic tool for neuropharmacology, mood disorder, and neurodegenerative disease research.

• Addressing Lidocaine with Epinephrine Shortages in Dermatolo

  2026-04-24

  The referenced study investigates the persistent shortage of lidocaine with epinephrine in the United States, identifying manufacturing bottlenecks and regulatory practices as primary causes. The authors present evidence-based strategies to optimize the use of existing supplies, ensuring continued efficacy in dermatologic procedures while minimizing resource waste.

• Neomycin Sulfate: Mechanistic Leverage for Translational Res

  2026-04-24

  This article explores the multifaceted mechanistic actions of Neomycin sulfate, an aminoglycoside antibiotic, and provides strategic guidance for translational researchers. Integrating current literature, competitive benchmarking, and evidence from immunology and microbiome modulation, we outline how Neomycin sulfate enables next-generation RNA/DNA interaction and ion channel studies, with direct implications for immune research. The discussion uniquely bridges molecular mechanisms, protocol optimization, and emerging translational opportunities, offering a perspective beyond conventional product summaries.

• Nelfinavir Mesylate: HIV-1 Protease Inhibitor for Modern Res

  2026-04-23

  Nelfinavir Mesylate, a benchmark HIV-1 protease inhibitor, is now driving innovation in both HIV replication suppression and ferroptosis modeling. This article bridges clinical-grade antiretroviral applications with cutting-edge cell death research, offering stepwise protocols, troubleshooting tips, and insight into the compound's expanding utility in translational science.

• Cisapride (R 51619): Elevating Cardiotoxicity and 5-HT4 Rese

  2026-04-23

  This article advances thought leadership on Cisapride (R 51619) by synthesizing mechanistic insights, deep learning-enabled phenotypic screening, and translational strategy. Drawing from recent high-content screening with iPSC-derived cardiomyocytes and APExBIO's high-purity Cisapride, it offers actionable guidance for researchers aiming to bridge predictive cardiotoxicity with next-generation drug discovery.

• Novel Allosteric PDK4 Inhibitors for Metabolic Disease Thera

  2026-04-22

  This article examines the discovery of new allosteric pyruvate dehydrogenase kinase 4 (PDK4) inhibitors, focusing on compound 8c, which demonstrates nanomolar in vitro potency and promising in vivo efficacy against metabolic and allergic disease models. The study introduces a structurally distinct scaffold, providing insight for drug development targeting PDK4-driven pathologies.

• Patient-Derived Gastric Cancer Assembloids Advance Drug Test

  2026-04-22

  This study introduces a patient-specific gastric cancer assembloid model that integrates matched tumor organoids with primary stromal cell subpopulations, closely mimicking the cellular complexity of human tumors. The model enables more predictive drug response profiling and facilitates research into mechanisms of resistance and personalized therapy.

• O-GlcNAcylation Links Wnt Signaling and Osteoblast Metabolis

  2026-04-21

  The referenced study reveals O-GlcNAcylation as an essential mediator of Wnt-stimulated bone formation, demonstrating that this post-translational modification governs glycolytic rewiring and osteoblast differentiation. These insights clarify the metabolic underpinnings of Wnt-driven anabolism and provide new avenues for targeting bone formation disorders.

• CCG-1423: Expanding the Role of RhoA Inhibitors in Junctiona

  2026-04-21

  Explore how CCG-1423, a leading RhoA inhibitor, advances research beyond cancer by enabling precise interrogation of tight junction dynamics and viral entry. Discover insights that set this analysis apart from prior overviews, with actionable protocol guidance and cross-domain context.

• Transcription Termination Limits DNA Damage After WEE1 Inhib

  2026-04-20

  This study reveals that transcription termination plays a crucial role in preventing DNA damage following WEE1 inhibitor treatment, highlighting new mechanisms underlying replication stress in cancer cells. The findings suggest therapeutic opportunities by targeting transcription-replication conflicts to enhance cancer cell death.

406 records 17/28 page Previous Next First page 上5页 1617181920 下5页 Last page